Table 1.

Winthrop University Hospital’s recent tigecycline experience: primary outcomes.

Indication	n = cases (%)
cSSSIs	14 (41.2%)
C. difficile Infections	7 (20.6%)
MDR Klebsiella Infections	4 (11.8%)
Pneumonias	3 (8.8%)
cIAIs	2 (5.9%)
VRE Infections	2 (5.9%)
Post-operative infections	1 (2.9%)
Unknown	1 (2.9%)
Treatment Outcomes by Indication
cSSSIs—Success	13 (92.9%)
cSSSIs—Failures	1 (7.1%)
C. difficile Infections—Success	7 (85.7%)
C. difficile Infection—Failure	0 (0%)
MDR Klebsiella Infections—Success	3 (75%)
MDR Klebsiella Infections—Failure	1 (25%)
Pneumonias—Success	3 (100%)
Pneumonias—Failure	0 (0%)
cIAIs—Success	2 (100%)
cIAIs—Failure	0 (0%)
Post-operative infections—Success	1 (100%)
Post-operative infections—Failure	0 (0%)
Treatment Outcomes HDT
Success	23 (95.8%)
Failure	1 (4.2%)
Treatment Outcomes SDT
Success	4 (66.7%)
Failure	2 (33.3%)
Overall Treatment Outcomes
Success	27 (79.4%)
Failure †	3 (8.8%)
Treatment Discontinuation due to ADE	2 (5.9%)
Death *	2 (5.9%)
Appropriate Use
Yes	28 (82.4%)
No	6 (17.6%)

cSSSIs = complicated skin & skin structure infections; MDR = multi-drug-resistant; cIAIs = complicated intra-abdominal infections; ADE = adverse drug effects; VRE = vancomycin-resistant enterococci; * = unrelated to infection or tigecycline; † Treatment failure associated with using standard dosing tigecycline (SDT).